PTO/SB/30 (5/2000)

Approved for use through xx/xx/xxxx. OMB 0651-0031
U.S. Patent and Trademark Öffice: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REQUEST **FOR CONTINUED EXAMINATION (RCE)** TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application

Express Mail No.	EL 500 578 375 US	#
Application Number	09/428,674	西 IP/un
Filing Date	October 27, 1999	王 四 112/
First Named Inventor	Michael Nehls	DE BO
Group Art Unit	1631	司。□
Examiner Name	Ardin Marschel	20
Attorney Docket Number	8535-029-999	8 3 11

filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).					Examiner Name		Ardin Marschel	<b>あら</b>	3	3_				
				Protection Act of 1999 (AIPA).	Attorney Docket	Number	8535-029-999	ड्र ह	3 1	出 <u></u>				
This is a	This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.  NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant in Syish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.													
1.	Sι	ıbmi	mission required under 37 C.F.R. § 1.114											
a.	×	Pre	viously submitte											
	i.	⊠	Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on <u>February 15, 2002 and August 15, 2002</u> (Any unentered amendment(s) referred to above will be entered).											
	ii.	⊠	Consider the a	arguments and incorporate by ref	erence the Ap	peal Brief	previously filed on	Augus	<u>st 15, 2</u>	2002				
	iii.		Other											
b.		End	closed	sed										
	i.	×	Amendment Under 37 C.F.R. §1.111											
	ii.		Affidavit(s)/Declaration(s)											
	iii.		Information Di	sclosure Statement (IDS)										
	iv.		Other											
2. Miscellaneous														
a.	a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of3 months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)													
	Other													
3.	Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed													
. a.	Ø	The Director is hereby authorized to charge the following fees, or credit any overpayments, to Pennie & Edmonds LLP Deposit Account No. 16-1150:												
	i.	⊠		ired under 37 C.F.R. § 1.17(e), es										
	ii.	×		me fee required under 37 C.F.R. ion, the Petition for which is being			mated to be \$ <u>205</u>	(small en	<u>tity)</u> fo	or a <u>two</u>				
	iii.	⊠	Other: Fee und	der 37 C.F.R. § 1.17(i) \$130 for Sus	pension of Ac	tion								
b.		Che	eck in the amou	int of \$ enclosed										
ÇC.		Pay	ment by credit	Card (Form PTO-2038 enclosed)										
			, Si	IGNATURE OF APPLICANT, AT	TORNEY, OF	R AGENT I	REQUIRED	•						
Name (Print/Type) Laura A. Coruzzi			zi			Registration 30,742	No. (Attorney/Agent)							
Signature		A.	Connzi	10 7 1 1 1 40. 258	-	Date	February 3, 2003							
CERTIFICATE OF MAILING OR TRANSMISSION														
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  Commissioner For Patents, Box RCE, Washington, DC 20231, or by facsimile transmitted to fax no. 1-703- to the U.S. Patent and Trademark Office on the date indicated below.														
Name (Print/Type)			ne)			Registration	Registration No. (Attorney/Agent)							

Signature

FEB 0 3 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

Date

02/05/2003 CV0111 00000020 161150 09428674

01 FC:2801

375.00 CH



Express Mail No.: EL 500 578 375 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Nehls et al.

Application No.: 09/428,674

Filed: October 27, 1999

For: NOVEL HUMAN

POLYNUCLEOTIDES AND THE

POLYPEPTIDES ENCODED

**THEREBY** 

Confirmation No: 4973

Group Art Unit: 1631

Examiner: Marschel, Ardin H.

Attorney Docket No.: 8535-029-999

RECEIVED

## AMENDMENT UNDER 37 C.F.R.§1.111

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with Rule 114 of the Rules of Practice, please consider the amendments and remarks below responding to the Notification of Non-Compliance with 37 C.F.R. § 1.192(c) dated November 4, 2002 and an Advisory Action dated September 3, 2002. Applicants submit concurrently herewith (1) Exhibit A, a copy of the marked-up claims; (2) Exhibit B, a copy of the pending claims; (3) a Request For Continued Examination; and (4) a Petition for Extension of Time for two months from December 4, 2002 up to and including February 4, 2003.

## **IN THE CLAIMS**

- 3. (Twice Amended) An isolated polynucleotide comprising a contiguous stretch of at least [about] 60 nucleotides of [at least] any one of SEQ ID NOS:10-12, 15, 16.
- 10. (Amended) An isolated polynucleotide comprising a contiguous stretch of at least [about] 30 nucleotides of any one of SEQ ID NO:10, 11, 15, 16.
- 11. (Amended) An isolated polynucleotide comprising a contiguous stretch of at least [about] 100 nucleotides of [at least] any one of SEQ ID NO:9-17.